Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease
Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease
复制标题
DOI：
10.1164/ajrccm.162.2.9909025
复制
发表时间：
2000-08-01
影响因子：
24.7
通讯作者：
Barnes, PJ
中科院分区：
文献类型：
--
作者：
Paredi, P;Kharitonov, SA;Barnes, PJ
乙烷是脂质过氧化的产物，可以在呼出的空气中作为氧化应激的指标来测量。氧化/抗氧化失衡在慢性阻塞性肺疾病（COPD）的发病机制中起重要作用。因此，我们测量了22名COPD患者（平均年龄+/- SEM， 59 +/- 8岁，19名男性）呼出的乙烷，并将其与其他无创氧化应激和炎症标志物（如电化学测量的一氧化碳（CO）和化学发光测量的一氧化氮（NO））进行比较。呼出的乙烷在流量和压力控制的呼出过程中被收集到一个储存库中，丢弃被周围空气污染的死空间空气。用色谱法对收集的过期空气样本进行分析。与正常受试者（n = 14； 8名男性；年龄33 +/- 2.8岁）相比，未接受类固醇治疗的COPD患者（n = 12; FEV1, 58 +/- 6%）呼出的乙烷（分别为2.77 +/- 0.25和0.88 +/- 0.09 ppb, p < 0.05）、CO（5.96 +/- 0.50和2.8 +/- 0.25 ppm, p < 0.05）和NO（11.86 +/- 0.53和6.77 +/- 0.50 ppb, p < 0.05）水平升高。乙烷与FEV1相关（r = -0.67, p < 0.05）。接受类固醇治疗的患者（n = 10; FEV1, 56 +/- 2%）的乙烷水平（0.48 +/- 0.05 ppb）低于接受类固醇治疗的患者，而CO （5.99 +/- 0.63 ppm）和NO （9.11 +/- 0.53 ppb）水平在两个治疗组中相似。呼出的乙烷升高，与FEV1相关，并且在类固醇治疗的患者中显著降低，因此它可能与使用NO和CO来评估和监测COPD的氧化应激相补充。
Ethane is a product of lipid peroxidation and can be measured in the exhaled air as an index of oxidative stress. Oxidant/antioxidant imbalance is important in the pathogenesis of chronic obstructive pulmonary disease (COPD). Therefore, we measured exhaled ethane in 22 patients with COPD (mean age +/- SEM, 59 +/- 8 yr; 19 male) and compared it with other noninvasive markers of oxidative stress and inflammation such as carbon monoxide (CO), measured electrochemically, and nitric oxide (NO), measured by chemiluminescence. Exhaled ethane was collected during a flow and pressure-controlled exhalation into a reservoir, discarding dead space air contaminated with ambient air. A sample of the collected expired air was analyzed by chromatography. Compared with normal subjects (n = 14; eight men; age, 33 +/- 2.8 yr), patients with COPD not on steroid treatment (n = 12; FEV1, 58 +/- 6%) had elevated levels of exhaled ethane (2.77 +/- 0.25 and 0.88 +/- 0.09 ppb, respectively, p < 0.05), CO (5.96 +/- 0.50 and 2.8 +/- 0.25 ppm, p < 0.05) and NO (11.86 +/- 0.53 and 6.77 +/- 0.50 ppb, p < 0.05) levels. Ethane was correlated to FEV1 (r = -0.67, p < 0.05). Patients receiving steroid treatment (n = 10; FEV1, 56 +/- 2%) had lower levels of ethane (0.48 +/- 0.05 ppb) than did steroid-treated patients, whereas CO (5.99 +/- 0.63 ppm) and NO (9.11 +/- 0.53 ppb) levels were similar in the two treatment groups. Exhaled ethane is elevated, correlates with FEV1, and is significantly lower in patients treated with steroids, so it may be complementary to the use of NO and CO in assessing and monitoring oxidative stress in COPD.